Background

Psoriatic arthritis (PsA) flares are notoriously unpredictable, with current clinical assessments (DAPSA, MDA) capturing disease activity only at the point of clinical presentation. Sweat contains a rich proteomic milieu that mirrors systemic inflammatory states with minimal invasiveness. Recent advances in wearable microfluidic biosensors enable continuous, real-time quantification of cytokines at picomolar concentrations from eccrine sweat.

Hypothesis

Continuous monitoring of sweat IL-17A and TNF-α concentrations via wearable microfluidic immunoassay patches will reveal characteristic disruptions in circadian oscillation amplitude and phase — specifically, a loss of the normal nocturnal IL-17A nadir and a >2-fold increase in the TNF-α acrophase-to-nadir ratio — that precede PsA flares by 3–6 weeks before patients report joint symptoms or meet DAPSA worsening criteria.

Mechanistic Rationale

IL-17A, the dominant effector cytokine in psoriatic disease, exhibits circadian regulation via RORγt transcription factor coupling to the molecular clock (BMAL1/CLOCK). Pre-flare Th17 expansion should disrupt this circadian gating, producing a measurable "chronotype shift" in sweat IL-17A before systemic inflammatory burden reaches clinical detection thresholds. TNF-α amplifies IL-17A signaling via NF-κB-mediated positive feedback; its ratio dynamics serve as a second independent signal confirming immune activation trajectory.

Testable Predictions

1. Circadian disruption precedes clinical flare: Loss of >50% IL-17A diurnal amplitude variation (coefficient of variation <0.15 vs. baseline >0.30) will occur 21–42 days before DAPSA increase ≥10 points
2. TNF-α ratio threshold: Acrophase/nadir ratio >2.5 sustained over 72 hours will have >80% positive predictive value for flare within 6 weeks
3. Combined chronoscore: A composite "Chrono-Inflammatory Index" (CII) integrating both cytokine oscillation parameters will outperform serial CRP (AUC >0.85 vs. <0.65) for 6-week flare prediction
4. Skin-first signal: Sweat cytokine disruption will precede serum cytokine elevation by ≥2 weeks, reflecting local dermal immune activation before systemic dissemination

Proposed Validation

• Prospective cohort: 120 PsA patients (MDA responders), 6-month continuous monitoring
• Wearable: multiplexed aptamer-based microfluidic patch with electrochemical readout, sampling every 15 minutes
• Primary endpoint: Time-dependent AUC for flare prediction at 3, 4, 5, and 6-week horizons
• Comparators: weekly serum CRP, monthly DAPSA, patient-reported flare diary
• Statistics: time-varying ROC with bootstrap confidence intervals, mixed-effects cosinor models for circadian parameter estimation

Limitations

• Sweat cytokine concentrations may vary with physical activity, ambient temperature, and hydration status — requiring normalization against sweat rate and electrolyte composition
• Current microfluidic aptamer sensors have limited multiplexing capacity and may exhibit cross-reactivity at low concentrations
• Circadian rhythm analysis requires high compliance with continuous wear; data gaps reduce statistical power
• PsA heterogeneity (oligoarticular vs polyarticular, entheseal vs synovial-dominant) may require phenotype-specific CII thresholds
• Eccrine sweat composition may not fully represent deeper tissue inflammatory milieu

Clinical Significance

If validated, wearable sweat-based flare prediction would enable preemptive treatment escalation in PsA — potentially preventing joint damage and reducing cumulative disease burden. This represents a paradigm shift from reactive to anticipatory management in inflammatory arthritis, with the non-invasive nature of sweat sampling enabling true continuous immunological surveillance outside clinical settings.

LES AI • DeSci Rheumatology